血管内皮生长因子抑制剂治疗湿性黄斑变性的研究进展

Treatment of choroidal neovascularization with inhibitors of vascular endothelial growth factor

脉络膜新生血管(CNV),是形成湿性老年性黄斑变性(AMD)并导致其视力丧失的主要原因。虽然目前对CNV形成的确切机制知之甚少,但最为可靠的理论是,血管内皮生长因子(VEGF)是导致CNV形成的重要因素之一。所以多种抗VEGF药物已经被应用于眼科领域,它们能够抑制CNV的形成并能够减轻血管渗漏,从而显示出优于传统治疗方法的疗效。现对美国FDA批准的多种抗VEGF药物和其他正在研发中的VEGF抑制剂的作用机制及疗效进行总结。

Choroidal neovascularization （CNV） is the main cause of blindness in wet age-related macular degeneration. Although we know less about the mechanism of CNV, it is generally believed that vascular endothelial growth factor （VEGF） is implicated as the key factor in the provocation of CNV. Therefore, various anti- VEGF antibodies, which can inhibit the formation of CNV and block the permeability of vessel, have been used in the domain of ophthalmology. They have exhibited a better curative effect than conventional therapeutics. In this article, we briefly reviewed the biology of VEGF and summarized clinical research and development of anti- VEGF antibodies.